企業プロフィール
INmune Bio 株価・ニュース・カタリスト
- ティッカー:
- INMB
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
2.13 USD (-1.84%)
終値
最終更新: 2026年8月17日
37.8M USD
時価総額
株価変動の要因
As of Aug 17, 2026, INMB closed down 1.84% at $2.13. No new same-company headline was identified in the current news window.
企業概要
Innate-Immune Therapeutics
INmune Bio develops therapies that modify innate immune responses. Its programs span cell therapy, neuroinflammation and cancer biology.
CORDStrom
CORDStrom is an allogeneic umbilical-cord-derived stromal-cell therapy being developed for recessive dystrophic epidermolysis bullosa, a severe inherited skin disorder.
XPro in Alzheimer's Disease
XPro1595 is a selective soluble-TNF inhibitor in clinical development for early Alzheimer's disease. The program is designed to suppress harmful neuroinflammation while preserving beneficial transmembrane-TNF signaling.
INB03 Oncology Program
INB03 applies the same soluble-TNF mechanism to cancer, with preclinical work evaluating whether it can overcome treatment resistance and reduce metastasis in HER2-positive disease.
INKmune
INKmune is a cell-based medicine designed to prime a patient's natural-killer cells into tumor-killing memory-like cells. It is being evaluated in an open-label Phase 1/2 prostate-cancer study.
今後のカタリスト
- UK marketing-authorization submission for CORDStrom around mid-summer 2026.
- European Medicines Agency filing for CORDStrom following the UK submission.
- FDA BLA submission for CORDStrom in the fourth quarter of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。